Can supercharged immune cells stop leukemia from returning?

NCT ID NCT07237230

Recruiting now Disease control Sponsor: Donghua Zhang Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether infusing special immune cells called γδ T cells can prevent relapse in people with high-risk acute myeloid leukemia (AML) who have had a stem cell transplant. The trial will enroll 40 adults aged 18 to 65. The main goal is to see if the treatment improves relapse-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: γδ T cells (a type of immune cell)
What this could lead to: If it works, this could offer a new way to prevent leukemia from coming back after a stem cell transplant, potentially improving long-term survival.
What could go wrong: This is an early, small trial with only 40 participants. The treatment may not prevent relapse and could cause side effects like graft-versus-host disease or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH RISK ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.